August 20, 2020
IRT 3.2.0 acquires new models and extended annotations
(Moscow – 20.08.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, presents the new version of its Immune Response Template (IRT). IRT is an efficient and useful tool to boost and facilitate the development of QSP models in immunology and immuno-oncology therapeutic areas. By this point IRT has been developed into a fully-fledged database but InSysBio constantly goes further in its software advancement.
Actually, IRT Version 3.2.0 has been enhanced significantly in comparison with the previous one. First of all, it was extended by three new models of «cell passport» type, namely:
The new schemes and corresponding equations that describe the lifecycle of these cells were introduced in IRT 3.2. Moreover, the majority of parameters within the equations are identified. It should be outlined, that the annotations that include the description of parameter identification methods are also implemented in the Database. Some In vitro models that were used for fitting (in that cases it was conducted) can be also found in IRT Database 3.2.0.
Another significant update covers the annotations which now include the information about parameters and fitted in vitro data. Specifically, models used for fitting and the data that depicts fitting quality are represented in frames of the Database.
Additionally, some bugs of the previous version have been corrected by IRT team. Veronika Musatova, Head of IRT development team, comments on it, “We have checked and updated the parameters values calculated via the experimental data for the models of eosinophils, B cells and T cells. The information about the data sources (links to tables and pictures) for the parameters calculation was supplemented. We have also corrected minor inconsistencies between the schemes and equations of Mast cells and Langerhans cells models”.
Application of IRT allows to simplify routine work on QSP model development and calibration by using calibrated sub-models exported from IRT as building blocks. Thus, IRT team intends to further develop and update the software for both internal and external usage.
For more information about IRT Version 3.2.0, please, visit irt.insysbio.com.
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
← | June 2020 | → | ||||
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1
|
2
1.
02 Jun 2020 13:24
InSysBio to announce the launch of QSP model of COVID-19
The new open source project to be developed and updated Online
InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the launch of its fundamentally new project in response to the ongoing global threat, the open source QSP model of COVID-19. In accordance with its mission, which is to assist pharmaceutical industry to speed up the delivery of the cure to patients, InSysBio team could not stay aside. Thus, the aim of the new project is to develop QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
3
|
4
|
5
1.
05 Jun 2020 15:04
InSysBio to present IRT Navigator 3
InSysBio presents IRT Navigator 3 which is an application software providing intuitive interface to work with the Immune Response Template Database in accordance with the user’s needs. It supplies the navigation within the schemes and components and efficient development of QSP models based on IRT Database.
|
6
|
7
|
8
1.
08 Jun 2020 15:30
InSysBio to perform the first step in development of COVID-19 QSP model
InSysBio has performed the first step in the direction of development of QSP model of COVID-19 describing virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|
9
|
10
|
11
|
12
1.
12 Jun 2020 16:45
InSysBio to release the new version of Cytocon DB 1.1.6.4
We are glad to announce the release of the new version of Cytocon DB 1.1.6.4. The DB was significantly extended with new data due to well-coordinated workflow of Cytocon DB team and its new members. Namely, 54 diseases, 24 tissues, 42 molecules, 24 cells and 3701 concentrations were introduced.
|
13
|
14
|
15
|
16
|
17
1.
17 Jun 2020 15:48
InSysBio to welcome its new team member Dr. Neil Benson
InSysBio announces the appointment of Dr. Neil Benson as Principal Consultant in area of business development
(Edinburgh-Moscow-16.06.2020) InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, is proud to announce its new team member Dr. Neil Benson! Dr. Benson has joined InSysBio as Principal Consultant in area of business development of both INSYSBIO LLC and INSYSBIO UK LIMITED. In his capacity as Principal Consultant to InSysBio, he will support further development of the outstanding IO and AD QSP offering of the company.
|
18
|
19
|
20
|
21
|
22
1.
22 Jun 2020 17:04
InSysBio team posters to be presented at AACR Virtual Annual Meeting II
AACR Virtual Annual Meeting II has begun! American Association for Cancer Research Annual Meeting is held virtually this year on June 22-24 due to COVID-19 spread. Today InSysBio team's posters were published on AACR website
|
23
|
24
|
25
|
26
|
27
|
28
|
29
|
30
1.
30 Jun 2020 15:45
InSysBio to present COVID-19 QSP model further development
InSysBio continues to move forward in COVID-19 QSP model development. Its aim is to describe virus and host cell life cycles, innate and adoptive immune response and possible therapeutic treatments.
|